Limits...
Focal therapy for prostate cancer: The current status.

Marshall S, Taneja S - Prostate Int (2015)

Bottom Line: Minimally invasive therapies are increasingly being investigated in localized prostate cancer.Focal therapy offers a promising outlook for prostate cancer treatment, with the goal of effectively achieving cancer control while minimizing morbidity.Long term studies are needed.

View Article: PubMed Central - PubMed

Affiliation: NYU Langone Medical Center, New York, NY, USA.

ABSTRACT

Purpose: In an era of increasing prostate cancer incidence and earlier detection, the assessment of clinical significance of prostate cancer is critical. Minimally invasive therapies are increasingly being investigated in localized prostate cancer.

Methods and results: In this review, we discuss the current status of magnetic resonance imaging targeted fusion prostate biopsy and focal therapy for prostate cancer, its rationale, and techniques.

Conclusion: Focal therapy offers a promising outlook for prostate cancer treatment, with the goal of effectively achieving cancer control while minimizing morbidity. Long term studies are needed.

No MeSH data available.


Related in: MedlinePlus

Post-HIFU 3T magnetic resonance imaging: atrophic prostate total gland post-HIFU. HIFU, high-intensity focused ultrasound.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494637&req=5

fig4: Post-HIFU 3T magnetic resonance imaging: atrophic prostate total gland post-HIFU. HIFU, high-intensity focused ultrasound.

Mentions: The majority of published results using HIFU have investigated its efficacy as a whole-gland treatment (Fig. 4). Ganzer and colleagues recently reported 14-year follow-up data on oncological and functional outcomes in 538 men. The biochemical disease-free rate at 5 years was 81% and at 61% at 10 years.46 Previous studies have cited biochemical disease-free rate ranging from 45% to 84% at 5 years and 69% at 7 years, using ASTRO or Phoenix criteria.47 In the Ganzer study, metastatic disease was reported in 0.4–6% of low- and intermediate-risk patients, and 15.4% in high-risk patients. prostate-cancer-specific death occurred in 18 (3.3%) patients.46


Focal therapy for prostate cancer: The current status.

Marshall S, Taneja S - Prostate Int (2015)

Post-HIFU 3T magnetic resonance imaging: atrophic prostate total gland post-HIFU. HIFU, high-intensity focused ultrasound.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494637&req=5

fig4: Post-HIFU 3T magnetic resonance imaging: atrophic prostate total gland post-HIFU. HIFU, high-intensity focused ultrasound.
Mentions: The majority of published results using HIFU have investigated its efficacy as a whole-gland treatment (Fig. 4). Ganzer and colleagues recently reported 14-year follow-up data on oncological and functional outcomes in 538 men. The biochemical disease-free rate at 5 years was 81% and at 61% at 10 years.46 Previous studies have cited biochemical disease-free rate ranging from 45% to 84% at 5 years and 69% at 7 years, using ASTRO or Phoenix criteria.47 In the Ganzer study, metastatic disease was reported in 0.4–6% of low- and intermediate-risk patients, and 15.4% in high-risk patients. prostate-cancer-specific death occurred in 18 (3.3%) patients.46

Bottom Line: Minimally invasive therapies are increasingly being investigated in localized prostate cancer.Focal therapy offers a promising outlook for prostate cancer treatment, with the goal of effectively achieving cancer control while minimizing morbidity.Long term studies are needed.

View Article: PubMed Central - PubMed

Affiliation: NYU Langone Medical Center, New York, NY, USA.

ABSTRACT

Purpose: In an era of increasing prostate cancer incidence and earlier detection, the assessment of clinical significance of prostate cancer is critical. Minimally invasive therapies are increasingly being investigated in localized prostate cancer.

Methods and results: In this review, we discuss the current status of magnetic resonance imaging targeted fusion prostate biopsy and focal therapy for prostate cancer, its rationale, and techniques.

Conclusion: Focal therapy offers a promising outlook for prostate cancer treatment, with the goal of effectively achieving cancer control while minimizing morbidity. Long term studies are needed.

No MeSH data available.


Related in: MedlinePlus